Related Experiment Video
Updated: Jan 25, 2026

The use of Biofeedback in Clinical Virtual Reality: The INTREPID Project
Published on: November 12, 2009
siRNA therapeutics: a clinical reality
Phei Er Saw1, Er-Wei Song2,3,4
1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Small interfering RNA (siRNA) therapeutics, leveraging RNA interference (RNAi), are advancing into clinics. Key challenges remain in safe and effective siRNA delivery, despite breakthroughs like Onpattro.
Area of Science:
- Biotechnology
- Molecular Biology
- Pharmacology
Background:
- RNA interference (RNAi) discovery revolutionized gene silencing.
- Small interfering RNA (siRNA) therapeutics show immense potential for disease treatment.
- Despite progress, safe, efficient, and targeted siRNA delivery remains a significant hurdle.
Purpose of the Study:
- To review the historical progression and breakthroughs in siRNA therapeutics.
- To highlight the first FDA-approved RNAi therapeutic, Onpattro (Patisiran).
- To discuss current siRNA nanocarrier systems in clinical trials and remaining challenges.
Main Methods:
- Historical review of RNA interference (RNAi) and siRNA therapeutics.
- Analysis of key advancements and clinical applications.
- Examination of siRNA delivery systems, particularly nanocarriers.
Main Results:
- siRNA therapeutics have progressed significantly since the discovery of RNAi.
- Onpattro (Patisiran) represents a major milestone as the first FDA-approved RNAi therapeutic.
- Various siRNA nanocarriers are under investigation in clinical trials for improved delivery.
Conclusions:
- siRNA therapeutics are entering clinical practice, offering new treatment avenues.
- Effective delivery systems are crucial for the success of siRNA therapeutics.
- Overcoming remaining challenges in delivery and safety is essential for broader clinical adoption.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Small interfering RNAs (siRNA)
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Microorganisms in Medicine and Therapeutics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...

